Managed Access Program for Momelotinib in Myelofibrosis

Managed Access Program for Momelotinib in Patients With a Diagnosis of Intermediate or High-risk Myelofibrosis (MF), Including Primary Myelofibrosis (PMF) or Secondary Myelofibrosis (Post- Polycythemia Vera/ Essential Thrombocytopenia (PV/ET)), With Anaemia

Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.

Inclusion Criteria:

• Written informed consent can be obtained from the patient or legally authorised representative as per local regulations
• Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia
• 18 years or older (at the time consent is obtained)
• The patient is willing to abide by the contraception requirements.
• No known hypersensitivity to momelotinib, its metabolites, or any of the formulation excipients

Exclusion Criteria:

• Pregnant or breastfeeding female